Avita Medical, Inc. - Common Stock (RCEL)
Frequently Asked Questions About Avita Medical, Inc. - Common Stock (RCEL)
Has Avita Medical made any recent acquisitions?
While specific details on acquisitions should be verified through recent press releases or financial reports, Avita Medical actively seeks strategic opportunities to enhance its product portfolio. The company might engage in partnerships or acquisitions to further its goals in regenerative medicine.
How can investors track Avita Medical's stock performance?
Investors can track Avita Medical's stock performance through various financial news websites, stock market apps, and the NASDAQ platform. Additionally, the company regularly releases earnings reports, press releases, and updates that provide insights into its financial health and market position.
How does Avita Medical contribute to scientific research?
Avita Medical actively contributes to scientific research by collaborating with academic institutions, conducting clinical studies, and participating in conferences. The company aims to advance knowledge in regenerative medicine and foster innovation through scientific partnerships.
In what markets does Avita Medical operate?
Avita Medical operates primarily in the medical device and regenerative medicine markets, focusing on wound care, burn treatment, and scar management. Their products are marketed and sold in various regions, including North America, Europe, and Australia.
Is Avita Medical publicly traded?
Yes, Avita Medical is publicly traded on the NASDAQ stock exchange under the ticker symbol RCEL. The company has undergone several rounds of fundraising and public offerings to support its growth and development.
What are the future growth prospects for Avita Medical?
The future growth prospects for Avita Medical are promising, given the increasing demand for advanced wound care solutions and the growing awareness of regenerative medicine's potential. The company is well-positioned to capitalize on expanding market opportunities both domestically and internationally.
What are the key benefits of using RECELL®?
The key benefits of using RECELL® include faster healing times, reduced scar formation, and the ability to perform treatment directly at the point of care. The use of a patient's own cells minimizes the risk of rejection and complications associated with donor skin grafts.
What does Avita Medical, Inc. do?
Avita Medical, Inc. is a regenerative medicine company that specializes in developing and commercializing innovative solutions for wound care and scar management. Their proprietary technology enables the effective treatment of a variety of skin-related conditions, primarily through the use of living cell therapies.
What impact did COVID-19 have on Avita Medical's operations?
Like many companies, Avita Medical experienced operational challenges due to COVID-19, including supply chain disruptions and changes in healthcare delivery. However, the company has adapted its strategies to continue supporting healthcare professionals while ensuring the safety of their products and services.
What is RECELL® used for?
RECELL® is used for the treatment of acute wounds, including thermal burns, and chronic wounds such as diabetic foot ulcers. The system aids in the rapid reconstruction of the skin, promoting effective healing with reduced recovery times.
What is the company’s role in addressing the global wound care burden?
Avita Medical plays a significant role in addressing the global wound care burden by providing innovative treatment solutions that improve healing times and patient care. By enhancing the accessibility and effectiveness of wound care treatments, the company contributes to reducing complications and healthcare costs associated with chronic wounds.
What is the main product of Avita Medical?
The main product offered by Avita Medical is RECELL®, a revolutionary device that enables healthcare providers to prepare and apply epidermal autografts at the point of care. This product utilizes the patient's own skin to create a suspension of skin cells, facilitating rapid healing while minimizing scarring.
What is the strategic vision of Avita Medical?
Avita Medical's strategic vision focuses on expanding its product offerings, increasing market penetration in existing markets, and developing new innovative solutions in the field of regenerative medicine. The company aims to improve patient outcomes through advanced wound care technologies.
What regulatory approvals has RECELL® received?
RECELL® has received regulatory approvals from various health authorities, including the U.S. Food and Drug Administration (FDA) and the European CE mark, allowing it to be marketed and sold in those regions for specified indications related to wound care.
What type of clinical trials has Avita Medical conducted?
Avita Medical has conducted multiple clinical trials to evaluate the safety and efficacy of RECELL® for various indications. These trials include studies focused on burn injuries, chronic wounds, and other skin-related conditions, with results that have supported its regulatory applications.
When was Avita Medical founded?
Avita Medical was founded in 1998. Originally established in Australia, the company has since grown to position itself as a leader in regenerative medicine, particularly in the field of skin healing and treatment.
Where is Avita Medical headquartered?
Avita Medical is headquartered in Valencia, California, USA. The company has additional operations and facilities to support its research and commercial endeavors across international markets.
Who are the competitors of Avita Medical?
Avita Medical faces competition from various companies in the wound care and regenerative medicine sectors. Key competitors include Organogenesis, A Cell, and Mimedx, all of which offer products aimed at improving wound healing and skin regeneration.
Who are the key executives at Avita Medical?
Key executives at Avita Medical include professionals with extensive experience in the medical device industry and regenerative medicine. Their leadership steers the company's strategic direction and drives innovation to advance its mission of transforming wound care.
What is the current price of Avita Medical, Inc. - Common Stock?
The current price of Avita Medical, Inc. - Common Stock is 4.750
When was Avita Medical, Inc. - Common Stock last traded?
The last trade of Avita Medical, Inc. - Common Stock was at 4:00 pm EDT on August 21st, 2025
What is the market capitalization of Avita Medical, Inc. - Common Stock?
The market capitalization of Avita Medical, Inc. - Common Stock is 121.02M
How many shares of Avita Medical, Inc. - Common Stock are outstanding?
Avita Medical, Inc. - Common Stock has 25.48M shares outstanding.